Altre lingue Ionis Pharmaceuticals, Inc.

Azioni

IONS

US4622221004

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 01/05/2024			Variaz. 5gg	Var. 1 gen.
43,01 ^USD	+4,24%		+1,32%	-14,98%

10/04	IONIS PHARMACEUTICALS, INC. : Wolfe Research ha un'opinione positiva	ZM
09/04	IONIS PHARMACEUTICALS, INC. : Oppenheimer conferma il rating Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ionis Publishes 2023 Corporate Responsibility Report	25/04
Ionis to hold first quarter 2024 financial results webcast	23/04
North American Morning Briefing : Stock Futures -2-	11/04
North American Morning Briefing : Traders Await -2-	10/04
Ionis Pharmaceuticals : Listen to webcast	09/04
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome	08/04
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome	07/04
Ionis to present at upcoming investor conferences	01/04
Ionis Pharmaceuticals - Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology annual meeting	26/03
Sector Update: Health Care Stocks Gain Premarket Wednesday	13/03
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up	13/03
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial	13/03
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH	13/03
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224	13/03
Ionis Pharmaceuticals, Inc. Announces Executive Changes	29/02
Ionis announces new chief global product strategy officer to lead next phase of commercial growth	29/02
Ionis to present at upcoming investor conferences	28/02
Travere drug for rare kidney condition recommended for EU approval	23/02
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday	21/02
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell	21/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ionis Pharmaceuticals, Inc.

Azioni

IONS

US4622221004

Altre lingue

Filtri